晚期上皮性卵巢癌初次治疗前评估:[18F]FDG PET/CT 容积参数与肿瘤标志物 HE4、CA125 的相关性
本研究纳入 66 例晚期高级别上皮性卵巢癌患者,在初次治疗前进行 [18F]FDG PET/CT 及血清 HE4、CA125 检测,计算全身代谢肿瘤体积(wb_MTV)和全身总病灶糖酵解(wb_TLG),并按 40% 和 50% SUVmax 阈值及解剖区域分组。结果显示 wb_MTV 和 wb_TLG 与 CA125、HE4 均显著相关,其中 HE4 与 wb_MTV40 相关性最强(r=0.62,p<0.001),且 HE4 对腹膜癌病的预测优于 CA125。结论提示 HE4 在预测代谢肿瘤负荷方面优于 CA125,PET/CT 容积参数可用于客观评估肿瘤负荷及其解剖分布。
要点
- HE4 与 wb_MTV40 相关性最强(r=0.62,p<0.001),优于 CA125。
- HE4 对腹膜癌病 MTV40 的相关系数为 0.61(p<0.0001),CA125 仅 0.29(p=0.02)。
- 两种标志物均与腹外肿瘤负荷无正相关。
局限性
- 单中心研究,样本量 66 例,结论外推需谨慎。
- 回顾性设计,可能存在选择偏倚。
- 未报告 PET/CT 设备型号、扫描参数及参考标准细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Accurate assessment of disease extent is required to select the best primary treatment for advanced epithelial ovarian cancer patients. Estimation of tumour burden is challenging and it is usually performed by means of a surgical procedure. Imaging techniques and tumour markers can help to estimate tumour burden non-invasively. 2-[18F]FDG PET/CT allows the evaluation of the whole-body disease. This study aimed to correlate HE4 and CA125 serum concentrations with tumour burden evaluated by volumetric 2-[18F]FDG PET/CT parameters in advanced high-grade epithelial ovarian cancer.
METHODS: We included 66 patients who underwent 2-[18F]FDG PET/CT and serum tumour markers determination before primary treatment. Volumes of interest were delimited in every pathological uptake. Whole-body metabolic tumour volume (wb_MTV) and total lesion glycolysis (wb_TLG) were calculated summing up every VOI's MTV value. SUVmax thresholds were set at 40% (MTV40 and TLG40) and 50% (MTV50 and TLG50). In addition, four VOI subgroups were defined: peritoneal carcinomatosis, retroperitoneal nodes, supradiaphragmatic nodes, and distant metastases. MTV and TLG were calculated for each group by adding up the corresponding MTV values. TLG was calculated likewise.
RESULTS: wb_MTV and wb_TLG were found to be significantly correlated with serum CA125 and HE4 concentrations. The strongest correlation was observed between HE4 and wb_MTV40 (r = 0.62, p < 0.001). Pearson's correlation coefficients between peritoneal carcinomatosis MTV40 and tumour markers were 0.61 (p < 0.0001) and 0.29 (p = 0.02) for HE4 and CA125 respectively. None of these tumour markers showed a positive correlation with tumour load outside the abdominal cavity assessed by volumetric parameters.
CONCLUSION: HE4 performs better than CA125 to predict metabolic tumour burden in high-grade epithelial ovarian cancer before primary treatment. 2-[18F]FDG PET/CT volumetric parameters arise as feasible tools for the objective assessment of tumour load and its anatomical distribution. These results support the usefulness of HE4 and PET/CT to improve the stratification of these patients in clinical practice.
KEY POINTS: • In patients with high-grade advanced ovarian epithelial carcinoma, both CA125 and HE4 correlate to whole-body tumour burden assessed by PET/CT before primary treatment. • HE4 estimates peritoneal disease much better than CA125. • PET/CT volumetric parameters arise as feasible tools for the objective assessment of tumour load and its anatomical distribution.
引用
- Glickman A, Paredes P, Carreras-Diéguez N, et al. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125. Eur Radiol. 2021. PMID: 34586465. doi:10.1007/s00330-021-08305-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。